Cited by 417Hematopoietic Stem Cell TransplantationMesenchymal stem cell researchBlood disorders and treatments

Inflammation: a key regulator of hematopoietic stem cell fate in health and disease

Open access
Pietras, Eric M.·2017·Blood

Abstract

Hematopoietic stem cells (HSCs) are responsible for lifelong production of blood cells. At the same time, they must respond rapidly to acute needs such as infection or injury. Significant interest has emerged in how inflammation regulates HSC fate and how it affects the long-term functionality of HSCs and the blood system as a whole. Here we detail recent advances and unanswered questions at the intersection between inflammation and HSC biology in the contexts of development, aging, and hematological malignancy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2017-06-780882

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Chronic inflammation, often associated with increased IL-1 activity, is a common phenotype in individuals at risk for hematological malignancy, which can be related to several preexisting factors, including aging/tissue decline, genotoxin exposure, metabolic dysfunction, and/or autoimmune disease.

    “Chronic inflammation, often associated with increased IL-1 activity, is a common phenotype in individuals at risk for hematological malignancy, which can be related to several preexisting factors, including aging/tissue decline, genotoxin exposure, metabolic dysfunction, and/or autoimmune disease (Barreyro et al., 2018; Pietras, 2017).”

    From PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress (2021) · cites this paper as Pietras, 2017

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Dysregulated inflammatory signaling has emerged as a key partner alongside oncogenic mutations in the development and/or progression of hematological malignancy.

    “Dysregulated inflammatory signaling has emerged as a key partner alongside oncogenic mutations in the development and/or progression of hematological malignancy (Barreyro et al., 2018; Pietras, 2017).”
  • Quiescence prevents HSC depletion during chronic inflammation, indicating that multipotent progenitor (MPP) cells compensate the ongoing need, minimizing the necessity for HSCs to proliferate.

    “Quiescence prevents HSC depletion during chronic inflammation.This indicates that multipotent progenitor (MPP) cells, responsible for daily blood maintenance, compensate the ongoing need, thereby minimizing the necessity for HSCs to proliferate.25”

    From Inflammatory bone marrow microenvironment (2019) · cites this paper as [25]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pietras, E. M.
Affiliations
University of Colorado Anschutz (US)
Corresponding author
Pietras, Eric M.
Venue
Blood
Published
2017-10-12
Volume
130
Issue
15
Pages
1693-1698
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2751980430
Cited by
417
References
92
Citations by year
2026: 43 · 2025: 46 · 2024: 49 · 2023: 43 · 2022: 50 · 2021: 76 · 2020: 48 · 2019: 38 · 2018: 24
FWCI
4.78
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Boettcher Foundation
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (K01DK098315)
Topics
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Blood disorders and treatments
Keywords
hematopoietic stem cells, inflammation, HSC quiescence, HSC aging, hematopoiesis, hematologic malignancies
MeSH terms
Aging, Animals, Disease, Health, Hematopoietic Stem Cells, Humans, Inflammation, Cell Lineage

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review